E2F1 and breast carcinoma: A previous study indicated that ANKRD22 could serve as a transcription factor and activate the expression of E2F1 in lung cancer progression [24], which suggests that ANKRD22 might regulate other factors to affect breast cancer development and this needs further investigation.